TOG Review (RCOG Journal)
MRCOG Part 2
Maternal Medicine
Management of gynaecological cancer in pregnancy
Key Statistics
- 1 in 1000 — Malignancy in pregnancy (all types)
- 1–10/10,000 — Cervical cancer in pregnancy
- 2–10/100,000 — Malignant adnexal mass in pregnancy
Don't-miss facts
-
Do not perform a cervical smear in pregnancy; refer suspicious lesions for colposcopy and directed biopsy
-
MRI yes, CT no for staging in pregnancy; radioisotope therapy is contraindicated (crosses placenta)
-
Cone/LLETZ bleeding risk 4–15%; do it early. Lymphadenectomy very difficult >15 weeks
-
Adnexal surgery window 12–27 weeks; laparoscopy only if low risk and <20–22 weeks; open if high risk (avoid spillage/upstaging)
-
CA125 >65 IU/ml in 16% of pregnancies – do not use routinely; AFP physiologically raised but much higher with germ cell tumours
-
No chemotherapy in the first trimester; bevacizumab contraindicated; no breastfeeding on platinum/taxane (excreted >2 weeks)
-
Pelvic radiotherapy is not compatible with fetal life – if unavoidable, 3rd trimester, deliver by caesarean first and transpose ovaries out of the field
-
Vulval surgery: defer to postpartum if ≥36 weeks; previous periurethral/perivaginal excision is a relative contraindication to vaginal delivery
Delivery flags
Prior trachelectomy → caesarean mandatory Prior pelvic RT → IUGR, deliver ~34 weeks
Borderline ovarian tumour → continue pregnancy, aim vaginal delivery
Abbreviation Key
- LLETZ — large loop excision of the transformation zone
- CA125 — cancer antigen 125
- MDT — multidisciplinary team
- AFP — alphafetoprotein
- FIGO — International Federation of Gynecology and Obstetrics
- BSO — bilateral salpingo-oophorectomy
- MRI — magnetic resonance imaging
- GROINSS — GROningen INternational Study on Sentinel Nodes in Vulvar Cancer
- CT — computed tomography
- VEGF-A — vascular endothelial growth factor A
- NICE — National Institute for Health and Care Excellence
- TOP — termination of pregnancy
- RMI — risk of malignancy index
- IUGR — intrauterine growth restriction
Source: China S, Sinha Y, Sinha D, Hillaby K. Management of gynaecological cancer in pregnancy. The Obstetrician & Gynaecologist 2017;19:139–146. doi:10.1111/tog.12367
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).